Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M38,060Revenue $M16,671Net Margin (%)14.2Altman Z-Score3.2
Enterprise Value $M45,391EPS $4.6Operating Margin %15.9Piotroski F-Score5
P/E(ttm)8.8Beneish M-Score-2.7Pre-tax Margin (%)14.2Higher ROA y-yN
Price/Book2.910-y EBITDA Growth Rate %10.9Quick Ratio1.0Cash flow > EarningsY
Price/Sales1.35-y EBITDA Growth Rate %5.5Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow27.8y-y EBITDA Growth Rate %-2.3ROA % (ttm)9.3Higher Current Ratio y-yN
Dividend Yield %5.4PEG2.0ROE % (ttm)28.8Less Shares Outstanding y-yY
Payout Ratio %61.0Shares Outstanding M544ROIC % (ttm)14.2Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXRichard Pzena 2015-03-31 Add0.41%$36.39 - $39.82
($37.91)
$ 38.301%Add 27.49%5,028,418
BAXJoel Greenblatt 2015-03-31 Add0.13%$36.39 - $39.82
($37.91)
$ 38.301%Add 4622.98%244,934
BAXFirst Eagle Investment 2015-03-31 Reduce-0.12%$36.39 - $39.82
($37.91)
$ 38.301%Reduce 99.84%1,100
BAXDavid Dreman 2015-03-31 Add0.03%$36.39 - $39.82
($37.91)
$ 38.301%Add 124.77%7,876
BAXTweedy Browne 2015-03-31 Reduce-0.01%$36.39 - $39.82
($37.91)
$ 38.301%Reduce 0.29%2,564,814
BAXJohn Keeley 2015-03-31 Add0.01%$36.39 - $39.82
($37.91)
$ 38.301%Add 26.95%53,460
BAXCharles Brandes 2015-03-31 Reduce-0.01%$36.39 - $39.82
($37.91)
$ 38.301%Reduce 3.40%229,981
BAXMario Gabelli 2015-03-31 Reduce$36.39 - $39.82
($37.91)
$ 38.301%Reduce 4.66%164,850
BAXRichard Pzena 2014-12-31 Buy 1.5%$36.52 - $40.58
($38.95)
$ 38.30-2%New holding3,944,140
BAXBill Nygren 2014-12-31 Sold Out -0.75%$36.52 - $40.58
($38.97)
$ 38.30-2%Sold Out0
BAXFirst Eagle Investment 2014-12-31 Reduce-0.06%$36.52 - $40.58
($38.95)
$ 38.30-2%Reduce 32.14%676,637
BAXMario Gabelli 2014-12-31 Reduce-0.02%$36.52 - $40.58
($38.95)
$ 38.30-2%Reduce 23.14%172,900
BAXJoel Greenblatt 2014-12-31 Buy $36.52 - $40.58
($38.97)
$ 38.30-2%New holding5,186
BAXRobert Olstein 2014-09-30 Sold Out -0.59%$38.72 - $41.83
($40.64)
$ 38.30-6%Sold Out0
BAXDavid Dreman 2014-09-30 Buy 0.02%$38.72 - $41.83
($40.64)
$ 38.30-6%New holding3,397
BAXFirst Eagle Investment 2014-06-30 Add0.18%$39.1 - $40.98
($40.02)
$ 38.30-4%Add 90872.40%1,000,696
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$39.1 - $40.98
($40.02)
$ 38.30-4%Sold Out0
BAXJohn Keeley 2014-06-30 Buy 0.05%$39.1 - $40.98
($40.02)
$ 38.30-4%New holding37,150
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$39.1 - $40.98
($40.02)
$ 38.30-4%Sold Out0
BAXVanguard Health Care Fund 2014-03-31 Reduce-0.41%$36.12 - $39.57
($37.34)
$ 38.303%Reduce 77.96%531,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Shapazian Carole JDirector 2015-05-22Sell1,533$67.68-43.41view
STROUCKEN ALBERT P LDirector 2015-04-27Sell4,830$71.06-46.1view
STORM KORNELIS J.Director 2015-04-27Sell4,830$71.05-46.09view
GAVIN JAMES R IIIDirector 2015-04-27Sell4,830$71.06-46.1view
HELLMAN PETER SDirector 2015-02-06Sell4,830$71.32-46.3view
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-48.87view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-50.25view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-50.14view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-49.61view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-48.53view

Quarterly/Annual Reports about BAX:

News about BAX:

Articles On GuruFocus.com
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Live Off Your Monthly Dividend Portfolio Mar 19 2015 
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Best Stock Pick For Long Term Investors Feb 10 2015 
Richard Pzena's New Buys Feb 09 2015 
Richard Pzena's 5 New Q4 Stock Buys Feb 06 2015 
Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 
Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 

More From Other Websites
Baxter's Headwinds Mostly Temporary Jul 03 2015
Baxter Int'l. (BAX) Stock Falling After Price Target Cut Jul 02 2015
S&P Reaffirms Baxter Rating Following Baxalta Spinoff Jul 02 2015
BofA Upgrades Baxter International On 'Margin Story,' But Valuation Is Rich Jul 02 2015
Baxter Announces Early Results of Debt Tender Offers Jul 02 2015
Baxter Announces Early Results of Debt Tender Offers Jul 02 2015
Baxter downgraded by BofA/Merrill Jul 02 2015
Baxter Announces Pricing of Debt Tender Offers Jul 01 2015
Baxter Announces Pricing of Debt Tender Offers Jul 01 2015
Trending Now: Baxter International Jul 01 2015
10 Worst Health Care Stocks in the S&P 500 Jul 01 2015
Analysts' Actions -- Check Point Software, ConAgra, Dillard's and More Jul 01 2015
Health Care: A Few Stocks Still Offer Upside Jul 01 2015
Baxter's MAA for MM-398 Accepted in International Markets - Analyst Blog Jun 29 2015
Baxter Shares Bid Up Ahead Of Spinoff Jun 25 2015
Baxter Provides Update on BAX 335 Trial Ahead of Spin-Off - Analyst Blog Jun 25 2015
MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the... Jun 25 2015
Jim Cramer: Baxter International (BAX) Stock Has 'Real Value' Jun 25 2015
U.S. FDA Grants Priority Review for MM-398 New Drug Application Jun 25 2015
U.S. FDA Grants Priority Review for MM-398 New Drug Application Jun 25 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 1 year ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK